{"organizations": [], "uuid": "750270547e7ff6e31dc88393934447e8571470dd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/28/globe-newswire-strongbridge-biopharma-plc-to-host-conference-call-on-march-12-2018-to-announce-fourth-quarter-and-year-end-2017-financial.html", "country": "US", "domain_rank": 767, "title": "Strongbridge Biopharma plc to Host Conference Call on March 12, 2018 to Announce Fourth Quarter and Year-End 2017 Financial Results and Provide Corporate Update", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.006, "site_type": "news", "published": "2018-02-28T15:30:00.000+02:00", "replies_count": 0, "uuid": "750270547e7ff6e31dc88393934447e8571470dd"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/28/globe-newswire-strongbridge-biopharma-plc-to-host-conference-call-on-march-12-2018-to-announce-fourth-quarter-and-year-end-2017-financial.html", "ord_in_thread": 0, "title": "Strongbridge Biopharma plc to Host Conference Call on March 12, 2018 to Announce Fourth Quarter and Year-End 2017 Financial Results and Provide Corporate Update", "locations": [], "entities": {"persons": [{"name": "strongbridge biopharma plc", "sentiment": "neutral"}, {"name": "strongbridge", "sentiment": "none"}], "locations": [{"name": "dublin", "sentiment": "none"}, {"name": "ireland", "sentiment": "none"}, {"name": "pa.", "sentiment": "none"}, {"name": "trevose", "sentiment": "none"}], "organizations": [{"name": "nasd", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "DUBLIN, Ireland and TREVOSE, Pa., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will host a conference call with members of Strongbridge’s management team on Monday, March 12 at 8:30 a.m. ET to discuss the Company’s fourth quarter and year-end 2017 financial results and provide a corporate update. The conference call will follow the anticipated release of the Company’s financial results earlier that day.\nEvent Details\nStrongbridge will host a conference call on Monday, March 12 at 8:30 a.m. ET. To access the live call, dial 844-285-7153 (domestic) or 478-219-0180 (international) with conference ID 6497969. The conference call will also be audio webcast from the Company’s website at www.strongbridgebio.com under the “Investor/Webcasts and Presentations” section. A replay of the call will be made available for one week following the conference call. To hear a replay of the call, dial 855-859-2056 (domestic) or 404-537-3406 (international) with conference ID 6497969.\nAbout Strongbridge Biopharma\nStrongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's commercial portfolio within its rare neuromuscular and rare endocrine franchises includes Keveyis ® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, and Macrilen™ (macimorelin), the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency. The Company’s rare endocrine franchise also includes a clinical-stage pipeline of therapies: Recorlev™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in other conditions amenable to somatostatin receptor activation.\nContacts:\nCorporate and Media Relations\nElixir Health Public Relations\nLindsay Rocco\n+1 862-596-1304\nlrocco@elixirhealthpr.com\nInvestor Relations\nUnited States:\nThe Trout Group\nMarcy Nanus\n+1 646-378-2927\nmnanus@troutgroup.com\nEurope:\nFirst House\nMitra Hagen Negård\n+47 21 04 62 19\nstrongbridgebio@firsthouse.no\nUSA\n900 Northbrook Drive\nSuite 200\nTrevose, PA 19053\nTel. +1 610-254-9200\nFax. +1 215-355-7389\nSource:Strongbridge Biopharma plc", "external_links": ["https://www.globenewswire.com/Tracker?data=TxDlqMyM-_VzOeRNugr4xWQCUzyxW17P0wSFYvFKU2-NcJDtGYI6uyOcl9CKf5Xnafc3QtyZN-NF7ps9rtbrieMpyHdTVVVy3fDxrrIEacw=", "https://www.globenewswire.com/Tracker?data=GgwuFFBOLoOm90LtGmDWvnzuajZX2KJ2vpd-efr7-s3cLDd86d1N3inwPDaGGIROmhCpJPtR5_YGJ6suLZFuV3mfWjPGzk9p5FtGolxdVJr8Bq4WCElNbfqQY8YSvzLdoNvlUSrnukAZ2mBN8Oz3XUYj31JCrFv6wkHf19hTb1y59MNrvqOHWWVpTo2LwIqN-OiCXfFMRgSROfRdgri1Rbf2Jas6kkzANE652Ql89LZ_5tnljzg1O1tiIM1-U6sRtzHQcc7-JvYrlZb7M4CBiA==", "https://www.globenewswire.com/Tracker?data=9YxvgX4ZeQvRa6C0QM30bAn7Kixzx6Zk8MmDdhbR8wfipekCQslkmJgfAxWNBlqlwPeBO1hdJ3XiLWvxzYkbB2aEGTYvNfYQu7eM0kKHNkA=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/6a48dba0-8534-461c-b78f-01fc3b7290c1", "https://www.globenewswire.com/Tracker?data=DfhlEikZeWYqCCWWWkXqXzTAx_USnscwap2TkutKAu4VKtWI2DKK7P3E_0DwYGr-sxFWx72_bh9Ps4O1IcS8B7WEosujrCJltk0JLBxU5XCQIsXnMBy2hb9EogHepCXn"], "published": "2018-02-28T15:30:00.000+02:00", "crawled": "2018-02-28T18:42:30.004+02:00", "highlightTitle": ""}